Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 8, 2022, the Board of Directors (the "Board") of Achieve Life Sciences, Inc. (the "Company") appointed Vaughn Himes, PhD., as a director, effective March 14, 2022. Dr. Himes has not been appointed to a committee of the Board at this time.

In connection with Dr. Himes's appointment to the Board, and in accordance with the Company's non-employee director compensation program, he will receive an annual cash retainer of $40,000 for Board service. In addition, in accordance with the Company's 2018 Equity Incentive Plan (the "Plan"), on the effective date of his appointment, Dr. Himes will receive an initial stock option grant to purchase up to 6,600 shares of the Company's common stock with an exercise price equal to the closing stock price as quoted on the Nasdaq Stock Market on the grant date. The options will vest and become exercisable monthly over 36 months commencing one month from the date of grant. Dr. Himes will also enter into the Company's standard form of indemnity agreement.

There are no arrangements or understandings between Dr. Himes and any other persons pursuant to which they were selected as a directors. There are also no family relationships between Dr. Himes and any director or executive officer of the Company, and Dr. Himes has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses